| 36.91 Delayed Data As of Sep 13 |  -0.37 / -0.99%Today’s Change | 33.97 Today|||52-Week Range 46.47 | -15.44% Year-to-Date |
| Previous close | 37.28 |
| Today’s open | 37.39 |
| Day’s range | 36.61 - 37.60 |
| Volume | 22,864,873 |
| Average volume (3 months) | 24,661,609 |
| Market cap | $202.5B |
| Earnings growth (last year) | -46.78% |
| Earnings growth (this year) | -5.67% |
| Earnings growth (next 5 years) | +4.40% |
| Revenue growth (last year) | +2.10% |
| P/E ratio | 16.9 |
| Price/Sales | 4.86 |
| Price/Book | 3.30 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | -2.50 | -2.79% |
| MRKMerck | -0.15 | -0.18% |
| AZNAstraZeneca | -0.13 | -0.30% |
| LLYEli Lilly and Co | -0.58 | -0.52% |
| Next reporting date | October 29, 2019 |
| EPS forecast (this quarter) | $0.63 |
| Annual revenue (last year) | $53.6B |
| Annual profit (last year) | $11.2B |
| Net profit margin | 20.77% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Director, Chief Executive & Operating Officer Albert Bourla |
Chief Financial Officer & EVP-Business Operations Frank A. D'Amelio |
Corporate headquarters New York, New York |
